Department of Molecular Medicine

[ default picture ] Chun-Lin  LinPh.D.

Assistant Professor/Research

Profile and Contact Information | Research



Research Program

I am interested in cancer research at individual and population levels. I did my postdoctoral fellowship in prostate cancer diagnosis at single-cell level. Tumor cells shed into body fluids have the potential to serve as a surrogate for biopsies when assessing disease progression in patients. I investigated less-invasive approaches for prostate cancer diagnosis by analyzing whole genome copy number levels of single cells from body fluids, include urine and blood samples. The result identified several novel loci that can serve as potential targets for drug treatment in clinical application. I have also expanded my work into disparities in cancer incidence/mortality in South Texas compared to nationwide areas. Knowing that the Hispanics contribute to a significant amount of population in South Texas, the disparities also reflect the impact of the race/ethnicity factor on cancer issues. My future research will address cancer disparities by applying genomic information at individuals and demographics in the environment.


Selected Publications

  1. Lin C-L, Tan X, Lin C-K, Osmulski PA, Liss MA, Chen M, Chen A, Wang C-M, Lucio N, Liu J, Horning AM, Huang G, Mitsuya K, Wang Y, Taverna JA, Liu Z, Xu K, Jin VX, Lai Z, Wang Q, Kirma N, Thompson Jr IM, Gaczynska ME, Chen C-L, Huang T H-M. Exfoliated single-cell genomics for assessing prostate cancer progression and treatment options. (In submission)

  2. Lin C-L, Huang G, Chen M, Chen M, Kusi M, Hsu Y-T, Tan X, Hsu P-Y, Kirma N, Chen C-L, Lin C-H, Lathrop K, Elledge R, Kaklamani V, Huang T H-M, Mitsuya K. Integrative genetic and epigenetic analysis in breast carcinoma identifies a druggable amplification event at 17q23 for targeted therapeutic intervention. (In submission)

  3. Horning AM, Wang Y, Lin C-K, Louie AD, Jadhav RR, Lin C-L, Kirma N, Liss MA, Kumar AP, Liu Z, Wang Q, Jin VX, Chen C-L, Huang TH-M. Single-cell RNA-seq reveals a hidden subpopulation of prostate cancer cells with enhanced cell cycle-related transcription and attenuated androgen response. Cancer Research (OnlineFirst Dec 12, 2017)

  4. Huang G, Osmulski PA, Bouamar H, Mahalingam D, Lin C-L, Liss MA, Kumar AP, Chen C-L, Thompson IM, Sun L-Z, Gaczynska ME, Huang T H-M. TGF-β signal rewiring sustains epithelial-mesenchymal transition of circulating tumor cells in prostate cancer xenograft hosts. Oncotarget 7(47): 77124-77137 (2016)

  5. Shen-Gunther J, Wang C-M, Poage GM, Lin C-L, Perez L, Banks NA, Huang T H-M. Molecular Pap smear: HPV genotype and DNA methylation of ADCY8, CDH8, and ZNF582 as an integrated biomarker for high-grade cervical cytology. Clinical Epigenetics 8-96 (2016)

  6. Sunkel B, Wu D, Chen Z, Wang C-M, Liu X, Ye Z, Horning AM, Liu J, Mahalingam D, Lopez-Nicora H, Lin C-L, Goodfellow PJ, Clinton SK, Jin VX, Chen C-L, Huang T H-M, Wang Q. Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence. Nucleic Acids Research 44: 4105-4122 (2016)

  7. Horning AM, Awe JA, Wang C-M, Liu J, Lai Z, Wang Y, Jadhav RR, Louie AD, Lin C-L, Kroczak T, Chen Y, Jin VX, Abboud-Werner SL, Leach RJ, Hernandez J, Thompson IM, Saranchuk J, Drachenberg D, Chen C-L, Mai S, Huang T H-M. DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence. The Prostate 75: 1790-1801 (2015)

  8. Mishra S, Lin C-L, Huang T H-M, Bouamar H, Sun L-Z. MicroRNA-21 inhibits p57Kip2 expression in prostate cancer. Molecular Cancer 13:212 (2014)

  9. Ghosh S, Gu F, Wang C-M, Lin C-L, Liu J, Wang H, Ravdin P, Hu Y, Huang T H-M, Li R. Genome-Wide DNA Methylation Profiling Reveals Parity-Associated Hypermethylation of FOXA1. Breast Cancer Research and Treatment 147: 653-659 (2014)

  10. Mishra S, Deng JJ, Gowda PS, Rao MK, Lin C-L, Chen C-L, Huang T H-M, Sun L-Z. Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer. Oncogene 33: 4097-4106 (2014)